WNK2 and melanoma: For instance, only patients with a BRAFV600E-mutated melanoma are expected to benefit from targeted therapies with BRAF/mitogen-activated protein kinase (MEK) inhibitors, while patients with a BRAFK601E-positive melanoma respond only to a minority of those drugs, such as trametinib (33).